In vivo determination of anxiolytic activity of a novel pyrazoloquinolinone-derivative at the benzodiazepine receptor

LOPEZ RIVILLI MARISA; BIGNANTE ANAHI; MOLINA, VICTOR; BRIÑON, MARGARITA; MOYANO, ELIZABETH L.

OURO PRETO, MG

Simposio; 5th Brazilian Symposium on Medicinal Chemistry; 2010

SOCIEDAD BRASILERA QUIMICA - MEDICINAL DIVISION

The pharmacological properties of benzodiazepines have made them the most common GABAA receptors modulating drugs in clinical use; consequently benzodiazepine binding site (BBS) is an interesting target for development of novel drugs.1 Several other types of compounds, such as the pyrazoloquinolinones (PQs) are known to bind to the BBS with high affinity, and show a continuous pharmacological activity as agonists, inverse agonist or antagonists.2and receptors modulating drugs in clinical use; consequently benzodiazepine binding site (BBS) is an interesting target for development of novel drugs.1 Several other types of compounds, such as the pyrazoloquinolinones (PQs) are known to bind to the BBS with high affinity, and show a continuous pharmacological activity as agonists, inverse agonist or antagonists.2 receptors modulating drugs in clinical use; consequently benzodiazepine binding site (BBS) is an interesting target for development of novel drugs.1 Several other types of compounds, such as the pyrazoloquinolinones (PQs) are known to bind to the BBS with high affinity, and show a continuous pharmacological activity as agonists, inverse agonist or antagonists.2